Conclusions : This systematic review and meta- analysis indicate that PDE5 inhibitors are effective and well tolerated to treat ED secondary to SCI compared with placebo , as measured by response to GEQ , SEP2 , SEP3 and incidence of adverse events .
PDE5 inhibitors could be considered as the first choice in the treatment of ED patients with SCI
Study design : Systemic review Objective : We carried out a systematic review and meta- analysis to assess the efficacy and safety of phosphodieterase-5 ( PDE5 ) inhibitors on erectile dysfunction ( ED ) secondary to spinal cord injury ( SCI ) .
Intracavernous injection of prostaglandin e1 in spinal cord injured patients with erectile dysfunction. A preliminary report
Our experience with intracavernous injection of prostagl and in E1 in spinal cord injured patients with neurogenic erectile dysfunction included 15 men . They received testing dosage starting from 5 µg with increasing dosage ( maximum 20 µg ) to achieve a rigid erection of Schramek 's grade 5 and lasting for at least 20 min . All of them had achieved functional erection adequate for coitus after treatment except one patient who had been proved to have venogenic impotence . We found that intracavernous injection of prostagl and in E1 had significantly improved the erectile condition . No systemic side effect or any other complication was noted except that pain at the injection site was complained of in two patients with incomplete lesion
Conclusions : This systematic review and meta- analysis indicate that PDE5 inhibitors are effective and well tolerated to treat ED secondary to SCI compared with placebo , as measured by response to GEQ , SEP2 , SEP3 and incidence of adverse events .
PDE5 inhibitors could be considered as the first choice in the treatment of ED patients with SCI
Study design : Systemic review Objective : We carried out a systematic review and meta- analysis to assess the efficacy and safety of phosphodieterase-5 ( PDE5 ) inhibitors on erectile dysfunction ( ED ) secondary to spinal cord injury ( SCI ) .